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Host-Targeted TB Therapies of Limited Efficacy So Far Shannon Weiman
Mycobacterium tuberculosis (Mtb) is notoriously diffıcult to eradicate even with combinations of antibiotics, leading researchers to pursue alternate strategies, including one aimed at bolstering host defenses against this pathogen. "Our inability to effectively treat all infected individuals necessitates a deeper understanding of the host-pathogen interface to facilitate new approaches," says Amy Barczak of the Ragon Institute and Massachusestts General Hospital in Boston, Mass. She was one of several experts who participated in the symposium "Aiming at Non-Conventional Approaches to TB Therapies," held at the 2016 ASM Microbe Conference in Boston last June.
Mtb exploits innate immunity to its advantage, according to Jeffery Cox of the University of California, Berkeley. Inside host macrophage cells, the pathogen ejects its DNA from phagosomes into the cytosol, where it is misidentifıed as viral DNA, tricking the host cell into mounting misdirected antiviral responses that favor Mtb survival. Specifıcally, various immune modulators, including OasL1 (2Ј-5Јoligoadenylate synthase-like protein 1), which controls type-1 interferon (IFN) production, are degraded. "We suspect that this primarily antiviral pathway has been co-opted by bacterial pathogens, perhaps primarily to elicit type-1 IFNs," he says, adding that blocking OasL1 ubiquitinylation might shift host immunity back toward antibacterial responses.
Mtb also exploits host cytokine sig-naling, further helping it survive within phagosomes, according to Priscille Brodin of the Institut Pasteur de Lille, France. She is investigating a mechanism by which phagocytosis of Mtb triggers cytokine signaling pathways that ultimately block phagosome acidifıcation. Cancer drugs that target these pathways may thwart Mtb's survival strategy, promoting phagosome maturation to kill internalized Mtb. Meanwhile, although a cyclic-di-AMPdependent cytosolic surveillance mechanism detects Mtb second messengers and activates antibacterial autophagy defenses, Mtb encodes a phosphodiesterase that degrades cyclic-di-AMP, allowing it to fly under the radar, according to William Bishai of John Hopkins University in Baltimore, Md. Phosphodiesterase inhibitors, including drugs widely used to treat erectile dysfunction, might give the upper hand back to the immune system, he points out.
Other drugs that promote autophagy defenses and benefıt the host include the antidepressant fluoxetine and the cancer drug gefıtinib, according to Barczak. "Fluoxetine induces autophagy and enhances production of tumor necrosis
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Recent developments involving microbiology and related science policy matters include:
• Following the G7 Summit Conference earlier this year, World Bank officials said they were helping to launch a Pandemic Emergency Financing facility, which will "create a new market for pandemic risk insurance, and ensure that resources get to the right place at the right time to the sites of outbreaks," factor (TNF)-␣," she says. Similarly, gefıtinib, which inhibits epidermal growth factor receptor (EGFR) signaling, enhances autophagy and attenuates Mtb infections in mice, she adds. "During infection, signaling through EGFR activates a p38 MAPK-signaling pathway that prevents macrophages from effectively responding to infection." Barczak also uses attenuated Mtb mutants and examines altered cytokine responses to reveal novel mechanisms by which Mtb undermines protective innate immune functions. In doing so, she identifıed a novel virulence factor required to permeabilize phagosomal membranes and elicit type I IFN responses described by Cox. Blocking such factors would free host immune responses to do their job of controlling infection without pathogen interference.
Although these host-directed therapies show promising results in vitro and in mice, their effıcacy is modest compared to antibiotics, making them candidates for adjuvant rather than antibiotic-replacement therapy, says Barczak. They "could play a strategic role in reducing the duration and complexity of treatment while effectively treating drug-resistant strains." Other complications can arise, adds Bishai. For example, although the antifıbrotic drug pirfenidone can effectively disrupt Mtb-containing granulomas in mouse lungs, it undermines antibiotic effıcacy and leads to drug resistance.
Shannon Weiman is a freelance writer in Boulder, Colo.
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Evidence of Beer-Making 5,000 Years ago at Site in Shaanxi, China
Carol Potera
Like home brewers today, people living on the Central Plain of China from 3400 to 2900 BCE actively concocted beer in period-appropriate vessels, which archaeologists recently unearthed at Mijiaya near the Chanhe River in Shaanxi province. These artifacts "represent a beer-making toolkit," and the Mijiaya site is the oldest beermaking facility ever discovered in China, according to Jiajing Wang at Stanford University in Stanford, Calif., and her collaborators. This date of about 5,000 years ago for early brewing in China is comparable to estimates for when ancient brewing began further west in Mesopotamia, including reference to the drinking of such beverages that appear in the Old Testament. Details appeared 26 April 2016 in Proceedings of the National Academy of Sciences (doi:10.1073/pnas.1601465113).
The pottery funnels, wide-mouth pots, and special jugs uncovered in Shaanxi were used to brew, fılter, and store beer, according to Wang. Yellow residues stuck to the interior surfaces of the vessels suggest that they once held beer. Moreover, nearby pottery stoves were likely used to heat ingredients and convert carbohydrates to simpler sugars for typical fermentations, she says.
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